Sharath S. Hegde, PhD
Dr. Hegde is the Vice President of Pharmacology at Theravance. Prior to joining Theravance in 1999, Dr. Hegde spent 9 years at Syntex Corporation, later acquired by Roche. Dr. Hegde obtained his Ph.D. in Pharmacology from the University of Houston and obtained his B.Pharm/M.Pharm degree in Pharmacy/Pharmacology from the University of Mumbai in India.
Dr. Hegde has over 20 years of leadership experience in strategic and tactical aspects of drug-discovery. In his current position at Theravance, Dr. Hegde leads a group of pharmacologists towards the discovery of novel small-molecule medicines for unmet medical needs. Dr. Hegde has been trained in classical ‘integrated pharmacology’. He possesses extensive experience in seeding new project ideas and designing preclinical studies to test hypothesis and enable discovery of first-in-class/best-in-class drugs in multiple therapeutic areas including infectious, cardiovascular, respiratory, urological, gastrointestinal and inflammatory diseases. He has played a leading role in the discovery of several NCEs at Roche and Theravance, including the marketed antibiotic Vibativ® (telavancin). He is the co-author of over 50 scientific publications and is currently serving on the editorial board of the journal ‘Naunyn Schmiedeberg’s Archives of Pharmacology'.